Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

UNH

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

UNH

AI Research Report

Powered by Claude

Ready to analyze UNH

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

B-
Stonvex Quant Grade
53.2/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
B+
74 / 100

Today's volume vs prior session average.

Volatility
B
64 / 100

Absolute daily price move vs peers.

News Flow
B-
58 / 100

24h article count relative to the universe.

Sentiment
F
10 / 100

AI-classified polarity of recent news.

Dollar Flow
B
67 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
F
15 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Healthcare →
LLY
Eli Lilly
$810.50
+2.30%
NVO
Novo Nordisk
—
—
JNJ
Johnson & Johnson
—
—
TMO
Thermo Fisher
—
—
WELL
Welltower
—
—
ABBV
AbbVie
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

UnitedHealth Group Inc

UnitedHealth Group Inc

Health Care·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1984-10-17

Factor Grades

View details →
C-
Overall score: 45/100
B
Valuation
C-
Growth
C-
Profitability
D-
Momentum
C-
Financial Health
  • SeekingAlpha·10h ago

    The Hidden Winners Inside SCHD - April 2026 Breakdown

    Schwab U.S. Dividend Equity ETF (SCHD) has outperformed in 2026, up over 11% YTD versus a flat SPY.

  • SeekingAlpha·11h ago

    UnitedHealth: Solid Annual Total Return Potential Makes It A Buy

    UnitedHealth (UNH) is a long-term BUY: EPS rebound, ~18% annual returns through 2030, strong balance sheet, 2.9% yield & dividend growth. Click to read more.

  • Yahoo·19h ago

    Analyst Raises Price Target on UnitedHealth Group (UNH), Keeps ‘Neutral’ Rating

    UnitedHealth Group Incorporated (NYSE:UNH) is included among the 15 Best Blue Chip Stocks to Buy Now. UnitedHealth Group Incorporated (NYSE:UNH) is a health care and well-being company with team members in two distinct and complementary businesses – its insurance wing, UnitedHealthcare, and its health services segment, Optum. On April 7, BofA analyst Kevin Fischbeck raised […]

  • Yahoo·23h ago

    UnitedHealth Group (UNH) Outperforms Broader Market: What You Need to Know

    UnitedHealth Group (UNH) closed the most recent trading day at $313, moving +2.85% from the previous trading session.

  • Yahoo·1d ago

    Patient Opportunity Equity Strategy Remains Firm on Its Thesis for UnitedHealth Group (UNH)

    Patient Capital Management, based in Baltimore, released its first-quarter 2026 investor letter for the “Patient Opportunity Equity Strategy,” available for download here. The strategy’s long-term value approach aims to build wealth over time. It returned -5.96% net of fees in Q1, compared to the S&P 500’s -4.33% return. As per three-factor performance attribution model the […]

  • Yahoo·2d ago

    The Great Rotation: Buy This Sector Before It Comes Back in Style

    Investors dislike these businesses right now, but that's what makes them great opportunities for investors focused on the long haul.

  • Yahoo·2d ago

    Market Crash: This Dividend Stock Becomes a No-Brainer Buy at a Discount

    The federal government is giving this company a major boost.

  • SeekingAlpha·2d ago

    UnitedHealth: Trust Is Broken - But The Model Isn't

    UnitedHealth faces a temporary margin reset, not a structural impairment, following margin pressure and guidance withdrawal. See why I rate UNH stock a Buy.

  • View all news →
⚠️
Dilution risk detected

1 offering-related filing in the last 60 filings. Latest: S-3ASR on 2026-03-02. View all →

Recent insider activity

View all →
  • 4FORM 4
    8d ago
  • 4FORM 4
    8d ago
  • 4FORM 4
    8d ago
  • 4FORM 4
    8d ago
  • 4FORM 4
    8d ago
📅 Earnings
NEW YORK STOCK EXCHANGE, INC.After-hours
UnitedHealth Group Inc
Health Care
$314.19
$1.19 (+0.38%)
After-hrs · vs prev close $313.00
Open
$312.51
Prev close
$313.00
Day range
$312.51 – $319.62
52W range
$234.60 – $606.36
Mkt cap
$284.10B
P/E
23.1
EPS
$13.19
Beta
0.45

Fundamentals

Valuation
Market Cap
$284.10B
P/E (TTM)
23.10S&P avg ~22
P/S (TTM)
0.62S&P avg ~2.8
P/B
2.99S&P avg ~4.5
P/FCF
16.03S&P avg ~26
EPS (TTM)
$13.19
Book/sh
$110.49
Cash/sh
$42.07
Profitability
Gross Margin
—avg ~45%
Operating Margin
4.18%avg ~15%
Net Margin
2.69%avg ~12%
ROE
12.50%avg ~18%
ROA
3.88%avg ~7%
ROI
6.84%
Payout Ratio
65.66%
FCF/sh
—
Growth & Health
Rev Growth YoY
11.81%
Rev Growth 5Y
11.72%
EPS Growth YoY
-14.94%
EPS Growth 5Y
-3.76%
Current Ratio
—
Quick Ratio
0.75
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.45
52W High
$606.36
52W Low
$234.60
Avg Vol (10D)
8.66M
Avg Vol (3M)
8.87M
Div Yield
2.82%
Div/sh (TTM)
—
Analyst
Buy (34)
Price Performance
5D+1.71%
MTD+15.67%
3M-9.76%
6M-12.76%
YTD-5.18%
1Y-47.34%

Analyst Consensus

Buy
Based on 34 analysts
Period: 2026-04-01
24 Buy (71%)8 Hold (24%)2 Sell (6%)
Rating Distribution
Strong Buy
6
Buy
18
Hold
8
Sell
1
Strong Sell
1
Trend
2026-04
24/8/2
2026-03
23/9/2
2026-02
23/9/2
2026-01
22/9/2